WO2001062289B1 - Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant - Google Patents

Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant

Info

Publication number
WO2001062289B1
WO2001062289B1 PCT/US2001/005718 US0105718W WO0162289B1 WO 2001062289 B1 WO2001062289 B1 WO 2001062289B1 US 0105718 W US0105718 W US 0105718W WO 0162289 B1 WO0162289 B1 WO 0162289B1
Authority
WO
WIPO (PCT)
Prior art keywords
organism
photosensitive material
membrane
cell
cellular
Prior art date
Application number
PCT/US2001/005718
Other languages
French (fr)
Other versions
WO2001062289A3 (en
WO2001062289A2 (en
Inventor
Merrill A Biel
Original Assignee
Advanced Photodynamic Technolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/514,070 external-priority patent/US7229447B1/en
Application filed by Advanced Photodynamic Technolo filed Critical Advanced Photodynamic Technolo
Priority to AU2001239835A priority Critical patent/AU2001239835A1/en
Priority to EP01914446A priority patent/EP1263465B9/en
Priority to JP2001561353A priority patent/JP2003531828A/en
Priority to CA2401624A priority patent/CA2401624C/en
Publication of WO2001062289A2 publication Critical patent/WO2001062289A2/en
Publication of WO2001062289A3 publication Critical patent/WO2001062289A3/en
Publication of WO2001062289B1 publication Critical patent/WO2001062289B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a method of photoeradication of cellular and acellular organisms including the steps of providing a surface acting agent in association with a cellular or acellular organism, the surface acting agent disorienting a membrane structure so that said membrane no longer functions as an effective osmotic barrier; providing a photosensitive material in association with the cellular or acellular organism; and applying light in association with the cellular or acellular organism to cause a disruption of the organism. The method according to the present invention may be utilized in invitro and invivo treatment protocols for infections, sterilization procedures, cancer cell eradication, virus and fungus eradication, spore eradication, and biofilm organism eradication. Additional aspects of the invention include particular combinations of photosensitive materials and surfactants for use in photodynamic therapies.

Claims

AMENDED CLAIMS
[received by the International Bureau on 13 May 2002 (13.05.02); original claims 1,15, 29, 36, 49, 60, 61, 71, 75, 80 and 87 amended; remaining claims unchanged (4 pages)]
1. (amended) A method of photodynamic disruption of cellular organisms
comprising:
providing a surface acting agent in association with a cellular organism, said surface
acting agent having ionophoric properties and disorienting a cell membrane so that said cell
membrane no longer functions as an effective osmotic barrier;
providing a photosensitive material in association with the cellular organism, said photosensitive material being passed through the cell membrane and into the cell interior; and
applying light in association with the cellular organism thereby activating the
photosensitive material within the cell interior to cause a cellular disruption of the cellular
organism.
15. (amended) The method of cellular organism disruption of claim 1 wherein the
surface acting agent having ionophoric properties is selected from a group containing: an
anionic surfactant, a cationic surfactant, a non-ionic surfactant, and an amphoteric surfactant.
29. (amended) A method of photodynamic disruption of acellular organisms
comprising:
providing a surface acting agent in association with an acellular organism, said surface
acting agent having ionophoric properties and disorienting a membrane of the acellular
organism so that said membrane no longer functions as an effective osmotic barrier;
providing a photosensitive material in association with the acellular organism, said photosensitive material being accumulated within the membrane and cytoplasm of the
acellular organism; and applying light in association with the acellular organism thereby activating the photosensitive material within the membrane and cytoplasm
to cause a disruption of the acellular organism.
36. (amended) The method of acellular organism disruption of claim 29 wherein the
surface acting agent having ionophoric properties is selected from a group containing: an
anionic surfactant, a cationic surfactant, a non-ionic surfactant, and an amphoteric surfactant.
49. (amended) A method of photodynamic disruption of cells comprising the steps of: identifying an area of cell activity;
providing a concentration including a combination of a chemical agent and a
photosensitive material in association with the area of cell activity, said chemical agent
having ionophoric properties and disorienting a cell membrane so that said membrane no
longer functions as an effective osmotic barrier, and so that said photosensitive material is
able to pass through the disoriented cell membrane and into the cell interior; and
exposing the area of cell activity to light having a light wavelength, a light dosage and
a light dosage rate thereby activating the photosensitive material within the cell interior to cause photodynamic cellular disruption.
60. (amended) A treatment protocol for a living body having cancer cells, said
protocol comprising the steps of:
selecting a chemical agent to disrupt a cell membrane of a cancer cell; administering the chemical agent to the living body, said chemical agent having
ionophoric properties and disorienting a cancer cell membrane so that said membrane no
longer functions as an effective osmotic barrier; administering a photosensitive material to the living body, said photosensitive
material passing through the cancer cell membrane and accumulating within the cancer cell
interior; and
applying a light in association to the cancer cell, the light activating the photosensitive
material within the cancer cell interior thereby resulting in disruption of the cancer cell.
61. (amended) The treatment protocol according to claim 60 wherein the chemical agent having ionophoric properties is a selected one of the group including an anionic
surfactant, a cationic surfactant, a nonionic surfactant, and an amphoteric surfactant.
71. (amended) A treatment protocol for a living body infected with a microbial cell,
said protocol comprising the steps of:
selecting a chemical agent having ionophoric properties;
administering the chemical agent to the living body to disorient a cell membrane of a
microbial cell so that said cell membrane no longer functions as an effective osmotic barrier;
administering a photosensitive material to the living body, said photosensitive
material passing through the cell membrane of the microbial cell and accumulating within the
microbial cell interior; and applying a light in association to the microbial cell, said light activating the
photosensitive material within the microbial cell interior to cause disruption of the microbial
cell.
75. (amended) The treatment protocol accordmg to claim 74 wherein the surfactant is provided at a concentration yielding ionophoric properties and is a selected one of the group
31 including an anionic surfactant, a cationic surfactant, a nonionic surfactant, and an amphoteric
surfactant.
80. (amended) A kit for potentiation of a photodynamic therapy of a pathogenic
cellular or acellular organism, said photodynamic therapy utilizing a light source for a
photodynamic disruption of the pathogenic cellular or acellular organism, said kit comprising:
a surface acting agent adapted to be dispensed to the pathogenic organism, said
surface acting agent having ionophoric properties and disrupting a pathogenic organism membrane so that said membrane no longer functions as an effective osmotic barrier; and
a photosensitive material adapted to be dispensed to the pathogen organism, said
photosensitive material being passed through the pathogenic organism membrane and into the
pathogentic organism interior, whereby photosensitive material within the pathogenic
organism interior is reactive with light from the light source to result in a photodynamic
pathogenic organism disruption.
87. (amended) A kit assembly for potentiation of a photodynamic therapy of a
pathogenic organism, said photodynamic therapy utilizing a light source for a photodynamic
organism destruction, said kit assembly comprising:
a surface acting agent, said surface acting agent having ionophoric properties and
being adapted to disorientate a pathogenic organism membrane so that said membrane no
longer functions as an effective osmotic barrier; and
a photosensitive material, said photosensitive material passing through the pathogenic organism membrane and into the pathogenic organism cytoplasm, wherein said
photosensitive material within the photogenic organism cytoplasm is reactive with the light
source to result in the photodynamic destruction of the pathogenic organism.
32
PCT/US2001/005718 2000-02-26 2001-02-23 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant WO2001062289A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001239835A AU2001239835A1 (en) 2000-02-26 2001-02-23 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
EP01914446A EP1263465B9 (en) 2000-02-26 2001-02-23 Photodynamic cellular organism eradication using a photosensitive material and surfactant
JP2001561353A JP2003531828A (en) 2000-02-26 2001-02-23 Eradicate photodynamic cells and acellular organisms using photosensitizers and surfactants
CA2401624A CA2401624C (en) 2000-02-26 2001-02-23 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/514,070 US7229447B1 (en) 1998-08-25 2000-02-26 Photodynamic therapy utilizing a solution of photosensitizing compound and surfactant
US09/514,070 2000-02-26
US09/792,578 US8267982B2 (en) 1998-08-25 2001-02-23 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
US09/792,578 2001-02-23

Publications (3)

Publication Number Publication Date
WO2001062289A2 WO2001062289A2 (en) 2001-08-30
WO2001062289A3 WO2001062289A3 (en) 2002-05-02
WO2001062289B1 true WO2001062289B1 (en) 2002-07-25

Family

ID=27058084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005718 WO2001062289A2 (en) 2000-02-26 2001-02-23 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant

Country Status (6)

Country Link
US (1) US8267982B2 (en)
EP (1) EP1263465B9 (en)
JP (1) JP2003531828A (en)
AU (1) AU2001239835A1 (en)
CA (1) CA2401624C (en)
WO (1) WO2001062289A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517532B1 (en) 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
AU7568698A (en) 1997-05-15 1998-12-08 General Hospital Corporation, The Method and apparatus for dermatology treatment
CA2302044C (en) * 1997-08-25 2011-07-05 Advanced Photodynamic Technologies, Inc. Treatment device for topical photodynamic therapy and method of making same
DE69926348T2 (en) 1998-03-12 2006-06-01 Palomar Medical Technologies, Inc., Burlington SYSTEM FOR THE ELECTROMAGNETIC IRRADIATION OF THE SKIN
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
JP2005535370A (en) 2002-06-19 2005-11-24 パロマー・メディカル・テクノロジーズ・インコーポレイテッド Method and apparatus for treating skin and subcutaneous conditions
US7713294B2 (en) * 2002-08-28 2010-05-11 Nomir Medical Technologies, Inc. Near infrared microbial elimination laser systems (NIMEL)
EP1555948A2 (en) 2002-10-23 2005-07-27 Palomar Medical Technologies, Inc. Phototreatment device for use with coolants and topical substances
CA2515695A1 (en) 2003-02-10 2004-10-07 Palomar Medical Technologies, Inc. Light emitting oral appliance and method of use
CA2541369A1 (en) * 2003-09-05 2005-04-21 The General Hospital Corporation Photodynamic inactivation of bacterial spores
US20050053895A1 (en) 2003-09-09 2005-03-10 The Procter & Gamble Company Attention: Chief Patent Counsel Illuminated electric toothbrushes emitting high luminous intensity toothbrush
US7544204B2 (en) * 2003-10-15 2009-06-09 Valam Corporation Control of halitosis-generating and other microorganisms in the non-dental upper respiratory tract
CA2547556A1 (en) * 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
US20050167438A1 (en) * 2004-02-02 2005-08-04 Max Minyayev Secure spill-proof configuration for child training cup
ES2401148T3 (en) * 2004-04-16 2013-04-17 Bredent Medical Gmbh & Co. Kg Preparation to photodynamically combat microorganisms and use of the preparation
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US20060173514A1 (en) * 2005-02-02 2006-08-03 Advanced Photodynamic Technologies, Inc. Wound treatment device for photodynamic therapy and method of using same
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
BRPI0616167A2 (en) 2005-09-15 2011-06-07 Palomar Medical Tech Inc optical skin characterization device
US20090087816A1 (en) * 2005-11-30 2009-04-02 Eric Bornstein Optical Therapeutic Treatment Device
GB0525504D0 (en) 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
ES2529714T3 (en) 2006-07-11 2015-02-24 Wista Laboratories Ltd. Synthesis and / or purification procedures for diaminophenothiazinium compounds
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
GB0823265D0 (en) 2008-12-20 2009-01-28 Convatec Technologies Inc Antimicrobial Composition
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US20110082410A1 (en) * 2009-10-01 2011-04-07 Ceramoptec Industries Inc. Method for Reducing Pain during Photodynamic Therapy
US20110280763A1 (en) * 2010-05-17 2011-11-17 Abbott Medical Optics Inc. Light-activated disinfection system
WO2012015820A1 (en) * 2010-07-30 2012-02-02 Advanced Photodynamic Technologies, Inc. Composition and method for photodynamic disinfection
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
KR102183581B1 (en) 2012-04-18 2020-11-27 싸이노슈어, 엘엘씨 Picosecond laser apparatus and methods for treating target tissues with same
US20150354096A1 (en) 2012-12-20 2015-12-10 Convatec Technologies Inc. Processing of chemically modified cellulosic fibres
EP3751684A1 (en) 2013-03-15 2020-12-16 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US9353092B2 (en) 2013-06-27 2016-05-31 University Of Notre Dame Du Lac Synthesis and use of croconaine compounds
KR101967625B1 (en) * 2014-08-27 2019-04-11 후지필름 가부시키가이샤 Composition for photodynamic therapy, sterilization method, sterilization system, and method for operating sterilization system
EP3586858A1 (en) 2015-10-01 2020-01-01 Photodynamic Inc. Novel polygonum cuspidatum extracts and their use as photodynamic inactivating agents
JP3223608U (en) * 2016-05-26 2019-10-24 サンディエゴ ステイト ユニバーシティ リサーチ ファンデーション Killing microorganisms with light using pulsed purple or blue light
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
WO2019165426A1 (en) 2018-02-26 2019-08-29 Cynosure, Inc. Q-switched cavity dumped sub-nanosecond laser
US11020605B2 (en) 2018-05-29 2021-06-01 Carewear Corp. Method and system for irradiating tissue with pulsed blue and red light to reduce muscle fatigue, enhance wound healing and tissue repair, and reduce pain
FI130369B (en) * 2018-10-26 2023-07-28 Koite Health Oy Method of treatment of biological surfaces
EP3666331A1 (en) 2018-12-11 2020-06-17 bredent medical GmbH & Co. KG Composition for the use in topical antimicrobial or anti-infective treatment of skin, soft tissue and wounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020183A (en) 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
US4181128A (en) * 1975-11-28 1980-01-01 Massachusetts Institute Of Technology Virus inactivation applicator and the like
US4656186A (en) 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4882234A (en) * 1986-11-12 1989-11-21 Healux, Inc. Storage-stable porphin compositions and a method for their manufacture
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4950665A (en) 1988-10-28 1990-08-21 Oklahoma Medical Research Foundation Phototherapy using methylene blue
US5571666A (en) 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
US5111821A (en) 1988-11-08 1992-05-12 Health Research, Inc. Fluorometric method for detecting abnormal tissue using dual long-wavelength excitation
US5041078A (en) 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US5262401A (en) 1991-06-28 1993-11-16 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
DE69314949T3 (en) * 1992-04-30 2003-02-20 Eastman Dental Inst London Oral cavity disinfection medication
US5260020A (en) * 1992-09-17 1993-11-09 Wilk Peter J Method and apparatus for catheter sterilization
US5676959A (en) 1994-12-09 1997-10-14 Photodye International, Inc. Phototoxic insecticidal composition and method for controlling insect populations
US5882328A (en) 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
NL9500216A (en) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Pharmaceutical composition for the treatment of herpes.
US5616342A (en) 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US6251127B1 (en) * 1997-08-25 2001-06-26 Advanced Photodynamic Technologies, Inc. Dye treatment solution and photodynamic therapy and method of using same
US6048359A (en) 1997-08-25 2000-04-11 Advanced Photodynamic Technologies, Inc. Spatial orientation and light sources and method of using same for medical diagnosis and photodynamic therapy
US6159236A (en) 1999-01-28 2000-12-12 Advanced Photodynamic Technologies, Inc. Expandable treatment device for photodynamic therapy and method of using same

Also Published As

Publication number Publication date
WO2001062289A3 (en) 2002-05-02
JP2003531828A (en) 2003-10-28
CA2401624A1 (en) 2001-08-30
EP1263465A2 (en) 2002-12-11
US8267982B2 (en) 2012-09-18
CA2401624C (en) 2011-08-16
WO2001062289A2 (en) 2001-08-30
EP1263465B1 (en) 2012-05-30
US20020183808A1 (en) 2002-12-05
EP1263465B9 (en) 2012-12-05
AU2001239835A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
WO2001062289B1 (en) Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
WO2002089750A3 (en) Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin
Mills The dental unit waterline controversy: defusing the myths, defining the solutions
Huang et al. Broad-spectrum antimicrobial effects of photocatalysis using titanium dioxide nanoparticles are strongly potentiated by addition of potassium iodide
Weiss et al. Virucide properties of cold atmospheric plasma for future clinical applications
Moghadas et al. Antimicrobial activity of a new nanobased endodontic irrigation solution: In vitro: study
EP1863502A2 (en) Method of treating skin ulcers using oxidative reductive potential water solution
BRPI0512563B8 (en) use of compounds in the preparation of a medicament for the prophylactic and/or therapeutic treatment of bacterial infections
US20130064712A1 (en) Composite comprising at least one type of perfluoroalkyl-perfluoro-phthalocyanine
Huang et al. Inactivation of dengue virus by methylene blue/narrow bandwidth light system
Lanzafame et al. Preliminary assessment of photoactivated antimicrobial collagen on bioburden in a murine pressure ulcer model
Hafner et al. Comparison of the bactericidal effect of cold atmospheric pressure plasma (CAPP), antimicrobial photodynamic therapy (aPDT), and polihexanide (PHX) in a novel wet surface model to mimic oral cavity application
AU2002342726A1 (en) Means for inactivating pathogenic agents on surfaces, instruments and in contaminated fluids
Wiegand et al. Cold atmospheric pressure plasmas exhibit antimicrobial properties against critical bacteria and yeast species
US9409037B2 (en) Enhanced anti-microbial PDT
WO2008024422A2 (en) Methods and compositions for decontamination and treatment of disease or injury
Delben et al. Low-temperature plasma: an effective approach against Candida albicans biofilm
Mandler et al. Disinfection of dental equipment—inactivation of Enterococcus mundtii on stainless steel and dental handpieces using surface micro-discharge plasma
Cooley et al. Indirect, non-thermal atmospheric plasma promotes bacterial killing in vitro and wound disinfection in vivo using monogenic and polygenic models of type 2 diabetes (without adverse metabolic complications)
Ting et al. Developments in antibacterial therapy: focus on physical stimuli approaches
Asnaashari et al. Antimicrobial activity of cold plasma treatment on acrylic denture bases: an in vitro evaluation
US7229447B1 (en) Photodynamic therapy utilizing a solution of photosensitizing compound and surfactant
EP0740940A3 (en) Process for disinfecting musculoskeletal tissue and tissues prepared thereby
Nandula et al. Plasma‐induced inactivation of Staphylococcus aureus biofilms: The role of atomic oxygen and comparison with disinfectants and antibiotics
Tsoukou Understanding the Potential of Plasma Activated Liquids for Biomedical Applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2401624

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 561353

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001914446

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001914446

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642